Editor’s Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS)
VIVUS, Inc. (NASDAQ:VVUS) announced positive results from TA-501, a placebo-controlled, multi-center study results that proved STENDRA (Avanafil)’s efficacy within 15 minutes for sexual activity in men suffering from Erectile Dysfunction (ED). This study has been designed to assess the efficacy of the drug. In the study, patients who used STENDRA indicated a statistically significant improvement over the placebo. …There is an increasingly growing market opportunity for ED treatments. In 2012, global sales exceeded $5.5B. An estimated 52% of men in the 40-70 years age range are affected by ED and age only increases its prevalence.
VIVUS Reports Study Results Demonstrating STENDRA Effective for Sexual Activity within 15 Mins in Men with ED (Benzinga)
VIVUS, Inc. (NASDAQ:VVUS) today announced positive results from a multicenter, placebo-controlled study, TA-501, designed to assess the efficacy of STENDRA™ (avanafil) in approximately 15 minutes. In the study, STENDRA patients achieved statistically significant improvement over placebo, in the mean proportion of attempts that resulted in erections sufficient for successful intercourse, as early as 10 minutes for the 200 mg dose and 12 minutes for the 100 mg dose after being taken. The market opportunity for ED medical treatments continues to grow, with worldwide sales exceeding $5.5 billion in 2012.
Vivus (VVUS) Shares Cross Above 200 DMA (Forbes)
In trading on Wednesday, shares of VIVUS, Inc. (NASDAQ:VVUS) crossed above their 200 day moving average of $14.23, changing hands as high as $14.26 per share. VIVUS, Inc. (NASDAQ:VVUS) shares are currently trading up about 0.4% on the day. The chart below shows the one year performance of VVUS shares, versus its 200 day moving average: …Looking at the chart above, VVUS’s low point in its 52 week range is $9.86 per share, with $31.21 as the 52 week high point — that compares with a last trade of $13.84.
Investors Applaud Vivus’ Erectile Dysfunction Drug (FoxBusiness)
Shares of VIVUS, Inc. (NASDAQ:VVUS) climbed more than 6% Wednesday after the drug developer boasted of positive results of its experimental erectile dysfunction drug, putting it one step closer to tapping a $5.5 billion market. The Mountain View, Calif.-based pharmaceutical giant said Stendra performed significantly better than the placebo, with patients achieving erections sufficient for intercourse as early as 10 minutes after taking the 200 mg dose and 12 minutes for the 100 mg dose.
Vivus Urges Stockholders To Support Board (Nasdaq)
VIVUS, Inc. (NASDAQ:VVUS), a biopharmaceutical company, Monday urged its stockholders to support the board and the management team at this critical juncture for the company. In a letter to stockholders, it advised them to protect the value of their investment in the firm by voting the GOLD proxy card. Noting that this is a critical juncture in the company’s history, VIVUS, Inc. (NASDAQ:VVUS) said FMC, which owns less than 10 percent of the company’s stock, is trying to seize control of 100 percent of the VIVUS, Inc. (NASDAQ:VVUS) Board and the company.
